MetaVia study highlights vanoglipel’s 10.2% VCTE fibrosis reduction versus placebo
MTVA•MetaVia published a preclinical study demonstrating that GPR119 agonist vanoglipel reduces liver fibrosis and inhibits key scar-formation pathways. Phase 2a clinical data showed vanoglipel cut fibrosis by 10.2% via VCTE, lowered ALT and TIMP1 levels, and improved CAP score and HbA1c.
1. Preclinical Data Validates Antifibrotic Effect
MetaVia’s preclinical research showed that activation of GPR119 by vanoglipel significantly reduced hepatic stellate cell activation, decreased extracellular matrix deposition, and inhibited signaling pathways responsible for scar tissue formation in liver fibrosis models.
2. Phase 2a Clinical Correlation
In the 16-week Phase 2a study, patients receiving vanoglipel experienced a 10.2% reduction in liver stiffness by VCTE versus a 10.1% increase for placebo, along with statistically significant declines in ALT and the fibrosis marker TIMP1, plus improvements in CAP score and HbA1c.
3. Mechanistic Insights and Development Path
The publication highlights dual metabolic and anti-fibrotic mechanisms of GPR119 agonism, reinforcing clinical observations and supporting vanoglipel’s potential as both a standalone and combination therapy for MASH and liver fibrosis.
